Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Investigational BACE inhibitors for the treatment of Alzheimer’s disease

Imbimbo, Bruno P., Watling, Mark · 2019 · Expert Opinion on Investigational Drugs

Abstract

Introduction : The amyloid hypothesis of Alzheimer's disease (AD) states that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represents the major causal event of the disease. Several small organic molecules have been synthesized and developed to inhibit the enzyme (β-site amyloid precursor protein cleaving enzyme-1 or BACE1) whose action represents the rate-limiting step in Aβ production. Areas covered : We reviewed the pharmacology and clinical trials of major BACE1 inhibitors. Expert opinion : In transgenic mouse models of AD, BACE1 inhibitors dose-dependently lower Aβ levels in brain and cerebrospinal fluid (CSF) but the evidence for attenuation or reversal cognitive or behavioral deficits is very scanty. In AD patients, BACE1 inhibitors robustly lower plasma and CSF Aβ levels and reduce brain plaques but without cognitive, clinical, or functional benefit. To date, seventeen BACE1 inhibitors have failed in double-blind, placebo-controlled clinical trials in patients with mild-to-moderate or prodromal AD, or in cognitively normal subjects at risk of developing AD. Several of these studies were prematurely interrupted due to toxicity or cognitive and behavioral worsening compared to placebo-treated patients. Elenbecestat, the last BACE1 inhibitor remaining in late clinical testing for AD, was recently discontinued due to safety concerns.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2019.1683160

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 6

  1. Vassar R, 2019, J Prev Alzheimers Dis, 6, 78
  2. Strobel G, 2019, Alzheimer Res Forum, 17
  3. Lo AC, 2018, J Prev Alzheimers Dis, 5, S37
  4. Shugart J, 2019, Alzheimer Res Forum, 12
  5. Caouette D Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer’s disease. Eisai’s press release;2019 Sept 13.
  6. Schneeberger A, 2015, J Prev Alzheimers Dis, 2, 103

Cited by

See all 135

Metadata

Authors
Imbimbo, B. P., & Watling, M.
Affiliations
  • Chiesi (Italy) (IT)
  • CNS & Pain Department, TranScrip Partners, Reading, UK
Corresponding author
Imbimbo, Bruno P.
Venue
Expert Opinion on Investigational Drugs
Published
2019-10-29
Volume
28
Issue
11
Pages
967-975
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2982501787
Cited by
132
References
61
Citations by year
2026: 9 · 2025: 8 · 2024: 21 · 2023: 22 · 2022: 20 · 2021: 38 · 2020: 14
FWCI
12.51
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
BACE1 inhibitors, Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid plaques, cerebrospinal fluid amyloid-beta, clinical trial failure, drug safety, cognitive decline, transgenic mouse model
MeSH terms
Drug Development, Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Mice, Transgenic, Drugs, Investigational, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Investigational BACE inhibitors for the treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/13543784.2019.1683160
The paper
Imbimbo, B. P., & Watling, M. (2019). Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2019.1683160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.